Debora de Melo Gagliato

Dr. Debora de Melo Gagliato

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DGDebora de Melo Gagliato
Debora de Melo Gagliato
DJDenis Leonardo Fontes Jardim
Denis Leonardo Fontes Jardim
MMMario Sergio Pereira Marchesi
Mario Sergio Pereira Marchesi
GHGabriel N. Hortobagyi
Gabriel N. Hortobagyi
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

7 July 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
DGDebora de Melo Gagliato
Debora de Melo Gagliato
XLXiudong Lei
Xiudong Lei
SGSharon H. Giordano
Sharon H. Giordano
VVVicente Valero
Vicente Valero
CBCarlos H Barcenas
Carlos H Barcenas
MGMariana Chavez Chavez Mac Gregor
Mariana Chavez Chavez Mac Gregor
Background: Delays in the initiation of therapy among patients with early stage breast cancer (BC) can negatively affect outcomes. Patients treated with neoadjuvant systemic chemotherapy (NSC) usually display tumors with high-risk features. Considering these high-risk characteristics and the evidence supporting adverse outcomes associated with delays in adjuvant chemotherapy initiation, we sought to determine whether a delay in NSC initiation is associated with overall survival (OS). Methods: We identified patients diagnosed between January 1995 and December 2015 with invasive primary BC (stage I–III) who received NSC at MD Anderson Cancer Center. Patients were categorized according to their time from BC diagnosis to NSC (in days) into three subgroups: 0-30, 31–60, and ≥61 days. Primary endpoint was OS. Descriptive statistics and Cox's proportional hazard models were used. Results: A total of 5,137 patients were included. Median follow-up was 6.5 years. The 5-year OS estimates according to time to NSC were 87%, 85%, and 83% in patients who received NSC within 0–30, 31–60, and ≥61 days after diagnosis, respectively (p = .006). In multivariable analysis, compared with time to NSC of 0–30 days, delayed NSC ≥61 days was associated with an increased risk of death (31–60 days: hazard ratio [HR] = 1.05 [95% confidence interval (CI) 0.92–1.19]; ≥61 days, HR = 1.28 [95% CI 1.06–1.54]). In stratified analyses, the association between delay in NSC initiation and increased risk of death was statistically significant for patients with stage I and II BC (31–60 days: HR = 1.22 [95% CI 1.02–1.47]; ≥61 days, HR = 1.41 [95% CI 1.07–1.86]) and among patients with HER2-positive tumors ( ≥61 days, HR = 1.86 [95% CI 1.21–2.86]). Conclusion: A delay in NSC initiation of more than 61 days after BC diagnosis was associated with an increased risk of death. Early initiation of NSC should be a priority; multidisciplinary teams must focus on coordination of care and patient-centered, timely treatment planning and delivery. Implications for Practice: The results of this study showed that a delay in neoadjuvant systemic chemotherapy initiation of more than 61 days after breast cancer diagnosis is associated with an increased risk of death; therefore, efforts must focus on early initiation of therapy, which should be a priority. Multidisciplinary teams must enhance coordination of care and patient-centered, timely treatment planning and delivery.

1 December 2014 in Clinical Breast Cancer
Verified
Journal Article
Closed access
DGDebora de Melo Gagliato
Debora de Melo Gagliato
DJDenis L. Fontes Jardim
Denis L. Fontes Jardim
GFGerald Falchook
Gerald Falchook
CTChad Tang
Chad Tang
RZRalph Zinner
Ralph Zinner
DHDavid S. Hong
David S. Hong

1 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DGDebora de Melo Gagliato
Debora de Melo Gagliato
ABAntonio C Buzaid
Antonio C Buzaid
JPJose Manuel Perez-Garcia
Jose Manuel Perez-Garcia
ALANTONIO LLOMBART-CUSSAC
ANTONIO LLOMBART-CUSSAC
Javier CortesJavier Cortes
Javier Cortes
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.

1 July 2022 in European Journal of Breast Health
Verified
Journal Article
Closed access
PSPriscila de Medeiros Souza
Priscila de Medeiros Souza
FCFilomena Marino Carvalho
Filomena Marino Carvalho
FAFernando N. Aguiar
Fernando N. Aguiar
DGDebora de Melo Gagliato
Debora de Melo Gagliato
ABAlfredo Carlos Simões Dornellas de Barros
Alfredo Carlos Simões Dornellas de Barros
This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters. GATA3 was analysed by immunohistochemistry in histological sections of tumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of tumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 expression. GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among tumors with low-GATA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity. High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors.

5 June 2024 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
DGDebora de Melo Gagliato
Debora de Melo Gagliato
TRTomas Reinert
Tomas Reinert
CRCláudio Rocha
Cláudio Rocha
MTMonique Tavares
Monique Tavares
SPSâmio Pimentel
Sâmio Pimentel
VCVivienne Castilho
Vivienne Castilho
Introduction Biological monoclonal antibodies play a pivotal role in cancer treatment, with biosimilars significantly enhancing their accessibility. In Brazil’s ethnically diverse setting, real-world evidence is crucial for assessing the effectiveness and applicability of these therapies in routine clinical practice. Methods We performed a multicentric, observational, prospective real-world study on biosimilar trastuzumab-dkst for adjuvant treatment of early HER2-positive breast cancer in Brazilian patients. Data were collected using a case-report form. Results Of the 176 recruited, we present data from the first 59 patients (mean age 51.7 ± 12.9 years) who had completed treatment with trastuzumab-dkst. The mean time from diagnosis to the first adjuvant treatment with trastuzumab-dkst was 5.5 ± 2.7 months. Of the patients, 59% of patients achieved at least a 30-month follow-up. The 31.7-month invasive disease-free survival rate (IDFS) was 94.5% (95% CI 83.9–98.2%) and median IDFS was not achieved, since only three patients had invasive disease recurrence. The overall survival rate was 100% until the last assessment. The observed adverse events were similar to those presented by other studies using biosimilar or reference trastuzumab. Four serious adverse events (8.5%) were observed. A reduction in left ventricular ejection fraction of at least 10% was observed in 16.9% of participants. There was no treatment interruption, and three participants (5.1%) had their trastuzumab-dkst dose reduced. Conclusion Our study reinforces the existing pivotal data, underscoring the real-world efficacy and safety of biosimilar trastuzumab-dkst in the adjuvant treatment for early HER2-positive breast cancer. The preliminary long-term effectiveness and safety data we present further validate trastuzumab-dkst’s role as a cost-saving alternative in oncological care. These findings have important implications for improving patient access to crucial treatments and for the more efficient use of healthcare resources. ClinicalTrials.gov Registration NCT03892655.